Dynamics of the Upper Respiratory Tract Microbiota and Its Association with Fatality in COVID-19 Patients
Lili Ren,Yeming Wang,Jiaxin Zhong,Dingyu Zhang,Yan Xiao,Jing Yang,Guohui Fan,Li Guo,Zijie Shen,Wen Liu,Lu Kang,Leisheng Shi,Xia Li,Qiong Li,Jizhou Li,Lin Di,Haibo Li,conghui wang,Ying Wang,Xinming Wang,Xiaohui Zou,Jiang Rao,Li Zhang,Jianbin Wang,Yanyi Huang,Bin Cao,Jianwei Wang,Mingkun Li
DOI: https://doi.org/10.2139/ssrn.3719095
2020-01-01
Abstract:The pandemic of Coronavirus disease 2019 (COVID-19) is ongoing globally, which is a big challenge for public health. Alteration of human microbiota had been observed in COVID-19. However, it is unknown how the microbiota is associated with the fatality in COVID-19. We conducted metatranscriptome sequencing on 588 longitudinal oropharyngeal swab specimens collected from 192 COVID-19 patients recruited in the LOTUS clinical trial (Registration number: ChiCTR2000029308) (including 39 deceased patients), and 95 healthy controls from the same geographic area. The upper respiratory tract (URT) microbiota in COVID-19 patients differed from that in healthy controls, while deceased patients possessed a more distinct microbiota. Streptococcus was enriched in recovered patients, whereas potential pathogens, including Candida and Enterococcus, were more abundant in deceased patients. Moreover, the microbiota dominated by Streptococcus was more stable than that dominated by other species. In contrast, the URT microbiota in deceased patients showed a more significant alteration and became more deviated from the norm after admission. The abundance of Streptococcus on admission, particularly that of S. parasanguinis, was identified as a strong predictor of fatality by Cox and L1 regularized logistic regression analysis, thus could be used as a potential prognostic biomarker of COVID-19. The generalization of the results in other populations and underlying mechanisms needs further investigations.